Roswell Park Cancer Institute

Revisiting patient diversity in clinical trials… again

Saturday, July 1, 2017

Minority groups have historically been excluded from clinical research, an inequity that has led to well-documented public health problems in which therapies tested primarily in Caucasian patients do not work as well in other ethnic and racial groups. This problem is famously exemplified by Sanofi’s blood thinner Plavix, which was approved in 1997 but slapped with a boxed warning in 2010 after researchers realized up to half of Asian and Pacific Islander populations cannot process the drug.

[Read More]

Roswell Park Cancer Institute spins out new company OmniSeq

Friday, June 12, 2015

OmniSeq has officially begun its spin out from Roswell Park Cancer Institute (RPCI) and will immediately begin commercializing its suite of innovative products that support a physician-driven, collaborative approach to genomic diagnostics—matching cancer patients to therapies tailored specifically to them. Collectively known as OmniSeq Precision Medicine Technology, OmniSeq provides oncology groups, hospitals and healthcare systems with the first-ever fusion of clinical genomics and a comprehensive information technology solution that provides easy access to actionable insights about their patient’s condition and available treatment options. Like Roswell Park, OmniSeq is based in Buffalo, N.Y.

[Read More]